Inovio Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INO)

$4.72 0.08 (1.72 %)
(As of 11/17/2017 02:17 PM ET)
Previous Close$4.72
Today's Range$4.79 - $4.62
52-Week Range$4.20 - $9.86
Volume906,385 shs
Average Volume1.28 million shs
Market Capitalization$418.97 million
P/E RatioN/A
Dividend YieldN/A
Beta2.91

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:INO
  • CUSIP: N/A
  • Web: www.inovio.com
Debt:
  • Current Ratio: 4.63%
  • Quick Ratio: 4.63%
Sales & Book Value:
  • Annual Sales: $35.37 million
  • Price / Sales: 12.05
  • Book Value: $1.80 per share
  • Price / Book: 2.62
Profitability:
  • Trailing EPS: ($1.18)
  • Net Income: ($73,740,000.00)
  • Net Margins: -1,290.76%
  • Return on Equity: -95.93%
  • Return on Assets: -75.53%
Misc:
  • Employees: 253
  • Outstanding Shares: 90,300,000
 

Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?

Inovio Pharmaceuticals declared a monthly dividend on Thursday, September 21st. Investors of record on Friday, September 29th will be paid a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 dividend on an annualized basis and a yield of 17.54%. The ex-dividend date is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.15. The biopharmaceutical company earned $2.60 million during the quarter, compared to analysts' expectations of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 1,290.76% and a negative return on equity of 95.93%. Inovio Pharmaceuticals's quarterly revenue was down 79.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.28) EPS. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?

10 brokerages have issued 12 month price targets for Inovio Pharmaceuticals' stock. Their predictions range from $10.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $20.20 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.

What are Wall Street analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio reported wider-than-expected loss in the third quarter of 2017 with revenue missing estimates. As the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Meanwhile highly lucrative immuno-oncology market has been the focus area of several big pharma giants which may pose intense competition to the candidates once approved. Shares of the company have underperformed the industry so far this year. However, we are positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging." (11/13/2017)
  • 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:

  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Peter D. Kies, Chief Financial Officer (Age 53)
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer (Age 49)
  • Mark L. Bagarazzi M.D., Chief Medical Officer (Age 56)
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board (Age 56)
  • George W. Bickerstaff III, Director (Age 61)
  • David B. Weiner, Director (Age 61)
  • Simon X. Benito, Independent Director (Age 72)
  • Angel Cabrera Ph.D., Independent Director (Age 49)

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wasatch Advisors Inc. (2.98%), Bank of New York Mellon Corp (0.42%), Allianz Asset Management GmbH (0.25%), Alyeska Investment Group L.P. (0.16%), Swiss National Bank (153,718.28%) and New York State Common Retirement Fund (0.14%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Russell Investments Group Ltd. and Stoneridge Investment Partners LLC. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner and Jong Joseph Kim. View Insider Buying and Selling for Inovio Pharmaceuticals.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., OxFORD Asset Management LLP, Wasatch Advisors Inc., Bank of New York Mellon Corp, ING Groep NV, Swiss National Bank, Allianz Asset Management GmbH and Belpointe Asset Management LLC. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $4.72.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $418.97 million and generates $35.37 million in revenue each year. The biopharmaceutical company earns ($73,740,000.00) in net income (profit) each year or ($1.18) on an earnings per share basis. Inovio Pharmaceuticals employs 253 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 10480 Wateridge Cir, SAN DIEGO, CA 92121-5773, United States. The biopharmaceutical company can be reached via phone at +1-858-5976006 or via email at [email protected]


MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  482
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Inovio Pharmaceuticals (NASDAQ:INO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $20.20 (327.97% upside)

Consensus Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)

Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)

Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017HC WainwrightReiterated RatingBuy$13.00N/AView Rating Details
10/18/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$11.00N/AView Rating Details
10/6/2017Citigroup Inc.Initiated CoverageBuy$10.00N/AView Rating Details
9/12/2017Maxim GroupReiterated RatingBuy$12.00LowView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies Group LLCReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
5/25/2016National Bank FinancialDowngradeOutperform Market Weight -> Sector Perform Market WeightN/AView Rating Details
3/28/2016DesjardinsDowngradeBuy -> HoldN/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Inovio Pharmaceuticals (NASDAQ:INO)

Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 17($0.25)($0.40)$10.27 million$2.60 millionViewN/AView Earnings Details
8/8/2017Q2 17($0.21)($0.13)$16.29 million$20.41 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/15/2014$0.22$0.22$4.63 million$4.66 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
5/7/2014$0.20$0.23$4.63 million$4.89 millionViewN/AView Earnings Details
3/22/2014$0.20$0.24ViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
Current Year EPS Consensus Estimate: $-1.12 EPS
Next Year EPS Consensus Estimate: $-1.28 EPS

Dividends

Dividend History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/21/2017Monthly$0.079/28/20179/29/201710/16/2017
8/22/2017Monthly$0.078/29/20178/31/20179/15/2017
7/25/2017Monthly$0.077/27/20177/31/20178/15/2017
6/23/2017Monthly$0.076/28/20176/30/20177/17/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ INO)

Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 24.98%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ INO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.20View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.00View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)

Latest Headlines for Inovio Pharmaceuticals (NASDAQ INO)

Source:
DateHeadline
Inovio Pharmaceuticals, Inc. (INO) Expected to Announce Quarterly Sales of $7.75 MillionInovio Pharmaceuticals, Inc. (INO) Expected to Announce Quarterly Sales of $7.75 Million
www.americanbankingnews.com - November 15 at 8:28 AM
Zacks Investment Research Downgrades Inovio Pharmaceuticals, Inc. (INO) to SellZacks Investment Research Downgrades Inovio Pharmaceuticals, Inc. (INO) to Sell
www.americanbankingnews.com - November 13 at 11:28 AM
Inovio Pharmaceuticals, Inc. (INO) Downgraded to "Sell" at Zacks Investment ResearchInovio Pharmaceuticals, Inc. (INO) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - November 13 at 11:28 AM
Inovio Pharma (INO) Presents Immuno-Oncology Advancements at SITCInovio Pharma (INO) Presents Immuno-Oncology Advancements at SITC
www.streetinsider.com - November 12 at 10:46 AM
Inovalis Real Estate Investment Trust (INO) Receives Consensus Rating of "Hold" from BrokeragesInovalis Real Estate Investment Trust (INO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 12 at 1:50 AM
Inovio Pharmaceuticals to Participate In Upcoming Investment ConferencesInovio Pharmaceuticals to Participate In Upcoming Investment Conferences
finance.yahoo.com - November 11 at 12:28 PM
What You Need to Know From Inovio Pharmaceuticals' Q3 UpdateWhat You Need to Know From Inovio Pharmaceuticals' Q3 Update
finance.yahoo.com - November 11 at 12:28 PM
Inovio (INO) Q3 Loss Wider Than Expected, Revenues MissInovio (INO) Q3 Loss Wider Than Expected, Revenues Miss
finance.yahoo.com - November 11 at 12:28 PM
Inovio Pharmaceuticals, Inc. (INO) Downgraded by ValuEngine to "Strong Sell"Inovio Pharmaceuticals, Inc. (INO) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - November 9 at 11:38 PM
EARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q3 Earnings Report
www.rttnews.com - November 9 at 6:49 AM
Inovio reports 3Q lossInovio reports 3Q loss
finance.yahoo.com - November 9 at 6:49 AM
Edited Transcript of INO earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of INO earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 6:49 AM
Inovio Pharmaceuticals, Inc. (INO) Releases Quarterly  Earnings Results, Misses Expectations By $0.15 EPSInovio Pharmaceuticals, Inc. (INO) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS
www.americanbankingnews.com - November 9 at 12:44 AM
Why Inovio Pharmaceuticals Stock Sank in October - Motley FoolWhy Inovio Pharmaceuticals Stock Sank in October - Motley Fool
www.fool.com - November 8 at 10:29 AM
Why Inovio Pharmaceuticals Stock Sank in October - Motley FoolWhy Inovio Pharmaceuticals Stock Sank in October - Motley Fool
www.fool.com - November 8 at 10:29 AM
Financial Survey: Ironwood Pharmaceuticals (IRWD) vs. Inovio Pharmaceuticals (INO)Financial Survey: Ironwood Pharmaceuticals (IRWD) vs. Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - November 6 at 3:26 AM
Inovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 MillionInovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 Million
www.americanbankingnews.com - November 2 at 10:52 AM
Inovio Pharmaceuticals (INO) & Oramed Pharmaceuticals (ORMP) Critical AnalysisInovio Pharmaceuticals (INO) & Oramed Pharmaceuticals (ORMP) Critical Analysis
www.americanbankingnews.com - November 2 at 3:08 AM
Inovio Pharma (INO) Initiates Study for Glioblastoma in Combination with Regenerons (REGN) PD-1 InhibitorInovio Pharma (INO) Initiates Study for Glioblastoma in Combination with Regeneron's (REGN) PD-1 Inhibitor
www.streetinsider.com - November 2 at 2:27 AM
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 InhibitorInovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
finance.yahoo.com - November 2 at 2:27 AM
Analyzing Inovio Pharmaceuticals (INO) and Fibrocell Science (FCSC)Analyzing Inovio Pharmaceuticals (INO) and Fibrocell Science (FCSC)
www.americanbankingnews.com - November 1 at 2:18 PM
Inovio Pharmaceuticals, Inc. (INO) Downgraded by BidaskClub to "Strong Sell"Inovio Pharmaceuticals, Inc. (INO) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - October 30 at 12:58 AM
Inovio Pharmaceuticals Is Now Oversold (INO)Inovio Pharmaceuticals Is Now Oversold (INO)
www.thestreet.com - October 26 at 6:56 PM
Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017 - NasdaqInovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017 - Nasdaq
www.nasdaq.com - October 26 at 1:52 PM
Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - October 26 at 1:52 PM
First Week Of INO December 15th Options TradingFirst Week Of INO December 15th Options Trading
www.thestreet.com - October 25 at 6:29 AM
Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical StudyInovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
finance.yahoo.com - October 25 at 6:29 AM
Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : October 24, 2017Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : October 24, 2017
finance.yahoo.com - October 25 at 6:28 AM
Montco vaccine developer posts positive results from Lassa fever virus studyMontco vaccine developer posts positive results from Lassa fever virus study
finance.yahoo.com - October 25 at 6:28 AM
Reviewing Inovio Pharmaceuticals (INO) & Its CompetitorsReviewing Inovio Pharmaceuticals (INO) & Its Competitors
www.americanbankingnews.com - October 24 at 12:30 PM
Have Investors Already Priced In Inovio Pharmaceuticals Inc’s (INO) Growth?Have Investors Already Priced In Inovio Pharmaceuticals Inc’s (INO) Growth?
finance.yahoo.com - October 23 at 7:36 PM
ETFs with exposure to Inovio Pharmaceuticals, Inc. : October 20, 2017ETFs with exposure to Inovio Pharmaceuticals, Inc. : October 20, 2017
finance.yahoo.com - October 21 at 6:52 PM
Corporate News Blog - Inovio Initiates Phase-1b/2 Cancer Efficacy TrialCorporate News Blog - Inovio Initiates Phase-1b/2 Cancer Efficacy Trial
finance.yahoo.com - October 19 at 5:31 AM
Inovio Pharmaceuticals, Inc. (INO) Receives Consensus Recommendation of "Hold" from AnalystsInovio Pharmaceuticals, Inc. (INO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 18 at 11:02 PM
Inovio Initiates Bladder Cancer Study With Roches Tecentriq - Nasdaq - NasdaqInovio Initiates Bladder Cancer Study With Roche's Tecentriq - Nasdaq - Nasdaq
www.nasdaq.com - October 18 at 1:41 AM
Inovio Initiates Bladder Cancer Study With Roche's TecentriqInovio Initiates Bladder Cancer Study With Roche's Tecentriq
finance.yahoo.com - October 18 at 1:41 AM
Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 ... - GlobeNewswire (press release)Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 ... - GlobeNewswire (press release)
globenewswire.com - October 16 at 3:39 PM
Inovio Pharmaceuticals, Inc. (INO) Cut to "Sell" at BidaskClubInovio Pharmaceuticals, Inc. (INO) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - October 14 at 8:22 AM
-$0.22 EPS Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter-$0.22 EPS Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - October 12 at 4:26 AM
ETFs with exposure to Inovio Pharmaceuticals, Inc. : October 9, 2017ETFs with exposure to Inovio Pharmaceuticals, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 7:56 PM
Inovio Pharmaceuticals, Inc. (INO) Now Covered by Analysts at Citigroup Inc.Inovio Pharmaceuticals, Inc. (INO) Now Covered by Analysts at Citigroup Inc.
www.americanbankingnews.com - October 7 at 6:06 PM
Inovio Pharma (INO) Says Positive Zika Vaccine Clinical Study Data Published in NEJM - StreetInsider.comInovio Pharma (INO) Says Positive Zika Vaccine Clinical Study Data Published in NEJM - StreetInsider.com
www.streetinsider.com - October 7 at 4:38 AM
Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 11:34 PM
Inovio Pharmaceuticals, Inc. (INO) PT Set at $13.00 by HC WainwrightInovio Pharmaceuticals, Inc. (INO) PT Set at $13.00 by HC Wainwright
www.americanbankingnews.com - October 6 at 9:12 AM
A Zika Vaccine Shows Signs of Success in an Early Human Trial - FortuneA Zika Vaccine Shows Signs of Success in an Early Human Trial - Fortune
fortune.com - October 6 at 8:43 AM
Brainstorm Health: Zika Vaccine, Sanofi/Regeneron Catch a Break, Does Obamacare Still ExistBrainstorm Health: Zika Vaccine, Sanofi/Regeneron Catch a Break, Does Obamacare Still Exist
fortune.com - October 6 at 12:24 AM
BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccineBRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine
www.reuters.com - October 6 at 12:24 AM
Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech MoversInovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers
finance.yahoo.com - October 6 at 12:23 AM
Zika vaccine shows promise in early human trial - ReutersZika vaccine shows promise in early human trial - Reuters
www.reuters.com - October 5 at 8:58 AM
Inovios Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine - GlobeNewswire (press release)Inovio's Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine - GlobeNewswire (press release)
globenewswire.com - October 5 at 8:58 AM

Social Media

Financials

Chart

Inovio Pharmaceuticals (NASDAQ INO) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.